# NCT04886804 (NCT04886804)

> Beamion LUNG-1: A Study to Test Different Doses of Zongertinib in People With Different Types of Advanced Cancer (Solid Tumours With Changes in the HER2 Gene)

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04886804
- Phase: PHASE1
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Boehringer Ingelheim
- Conditions: Neoplasm Metastasis; Non-Small Cell Lung Cancer
- Interventions: zongertinib
- Enrollment: 554
- Primary outcome: Phase Ia: Maximum Tolerated Dose (MTD)
- Primary outcome: Phase Ia: Number of patients with Dose Limiting Toxicities (DLTs) in the MTD evaluation period
- Primary outcome: Phase Ib - Cohorts 1, 2, 3 (enrolled from CTP v8.0), and 5: Objective response (OR) as assessed by central independent review
- Primary outcome: Phase Ib - Cohorts 3 (patients prior to CTP v8.0), 6, 7, 8, and 9: Objective response according to RECIST 1.1 by investigator assessment
- Primary outcome: Phase Ib: Cohort 4: Objective response according to Response Assessment in Neuro-Oncology for Brain Metastases (RANO-BM) by central independent review

## Commentary we found

- X threads: 7

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=nct04886804